Acambis PLC Announces Encouraging Safety And Immunogenicity Results From Phase 2 Study Of MVA3000 Smallpox Vaccine

Acambis plc (Acambis) (LSE: ACM, NASDAQ: ACAM) announces preliminary results from a Phase 2 trial of its Modified Vaccinia Ankara (MVA) smallpox vaccine, MVA3000. Acambis is co-developing MVA3000 with Baxter Healthcare SA (“Baxter"), which is providing process development and manufacturing services.
MORE ON THIS TOPIC